Global Subcutaneous Drug Delivery Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Usability;

Disposable and Reusable

By Disease Indication;

Auto-Immune Disorders, Neurological Disorders, Oncology Disorders, Hormonal Disorders, Allergy & Infectious Disorders, Ophthalmic Disorders, and Others

By Delivery System;

Autoinjector - [Spring Type, Motorized Type, and Wearable Type], Pen Injectors, Disposable - [Reusable and Syringes (Injector)], Pump, and Others

By Distribution Channel;

Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn240575181 Published Date: June, 2025 Updated Date: July, 2025

Subcutaneous Drug Delivery Market Overview

Subcutaneous Drug Delivery Market (USD Million)

Subcutaneous Drug Delivery Market was valued at USD 19,460.95 million in the year 2024. The size of this market is expected to increase to USD 36,686.61 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 9.5%.


Global Subcutaneous Drug Delivery Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 9.5 %


Study Period2025 - 2031
Base Year2024
CAGR (%)9.5 %
Market Size (2024)USD 19,460.95 Million
Market Size (2031)USD 36,686.61 Million
Market ConcentrationMedium
Report Pages316
19,460.95
2024
36,686.61
2031

Major Players

  • Becton Dickinson and Company
  • Novo Nordisk A/S
  • Johnson & Johnson
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Amgen, Inc.
  • F. Hoffmann-La Roche AG
  • Consort Medical plc
  • Eli Lilly and Company
  • Merck & Co.

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Subcutaneous Drug Delivery Market

Fragmented - Highly competitive market without dominant players


The Subcutaneous Drug Delivery Market is experiencing significant growth due to increasing demand for self-administration and minimally invasive techniques. With more than 60% of biologics now administered through subcutaneous routes, the market is rapidly evolving. This shift supports strategies focused on patient convenience, treatment compliance, and chronic disease management, opening wide-ranging opportunities for innovative formulation technologies. Companies are emphasizing expansion through improved drug compatibility with subcutaneous methods.

Rising Demand for Home-Based Care
Nearly 55% of therapies associated with autoimmune and oncologic conditions are now being reformulated for subcutaneous delivery to enable home-based care. This transition is encouraging collaborations between pharmaceutical companies and device developers to enhance delivery precision and safety. With technological advancements in wearable injectors and smart pens, the sector is witnessing sustained innovation that aligns with long-term growth strategies.

Shifts Toward Biologic Formulations
Biologics account for approximately 70% of drugs delivered subcutaneously, underlining a shift in formulation strategy across the market. The subcutaneous delivery route has become a preferred method for monoclonal antibodies and other complex therapeutics. This shift is not only enhancing bioavailability but also reducing the need for frequent hospital visits. As pharmaceutical firms push for technological advancements, device integration is becoming more precise and patient-centric.

Future Outlook and Market Opportunities
The market is poised for substantial opportunities, with over 65% of stakeholders investing in R&D for long-acting injectables and automated delivery systems. The future outlook is shaped by sustained interest in digital monitoring tools and AI-integrated delivery devices. These tools are enabling real-time dose management, increasing treatment adherence, and streamlining clinical workflows. As industry leaders continue to explore strategic pathways for expansion, the focus on safety, personalization, and automation will remain central.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Usability
    2. Market Snapshot, By Disease Indication
    3. Market Snapshot, By Delivery System
    4. Market Snapshot, By Distribution Channel
    5. Market Snapshot, By Region
  4. Subcutaneous Drug Delivery Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Technological Advancements
        2. Increasing Prevalence of Chronic Diseases
        3. Rising Geriatric Population
        4. Patient Preference for Minimally Invasive Treatments
      2. Restraints
        1. High Cost of Advanced Delivery Systems
        2. Stringent Regulatory Requirements
        3. Need for Cold Chain Logistics for Biologics
        4. Limited Awareness in Developing Regions
      3. Opportunities
        1. Expansion into Emerging Markets
        2. Development of Needle-free Injection Systems
        3. Integration with Digital Health Technologies
        4. Personalized Medicine and Tailored Drug Delivery Solutions
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Subcutaneous Drug Delivery Market, By Usability, 2021 - 2031 (USD Million)
      1. Disposable
      2. Reusable
    2. Subcutaneous Drug Delivery Market, By Disease Indication, 2021 - 2031 (USD Million)
      1. Auto-immune Disorders
      2. Neurological Disorders
      3. Oncology Disorders
      4. Hormonal Disorders
      5. Allergy & Infectious Disorders
      6. Ophthalmic Disorders
      7. Others
    3. Global Subcutaneous Drug Delivery Market, By Delivery System, 2021 - 2031 (USD Million)
      1. Autoinjector
        1. Spring Type
        2. Motorized Type
        3. Wearable Type
      2. Pen Injectors
      3. Disposable
        1. Reusable
        2. Syringes (Injector)
      4. Pump
      5. Others
    4. Subcutaneous Drug Delivery Market, By Distribution Channel, 2021 - 2031 (USD Million)
      1. Hospital Pharmacies
      2. Retail Pharmacies
      3. Online Pharmacies
    5. Subcutaneous Drug Delivery Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Becton Dickinson and Company
      2. Novo Nordisk A/S
      3. Johnson & Johnson
      4. Sanofi S.A.
      5. Teva Pharmaceutical Industries Ltd.
      6. Amgen, Inc.
      7. F. Hoffmann-La Roche AG
      8. Consort Medical plc
      9. Eli Lilly and Company
      10. Merck & Co.
  7. Analyst Views
  8. Future Outlook of the Market